Browse NME2

Summary
SymbolNME2
NameNME/NM23 nucleoside diphosphate kinase 2
Aliases NM23-H2; NDPKB; non-metastatic cells 2, protein (NM23B) expressed in; NDKB; NDPK-B; NM23B; PUF; HEL-S-155an; ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Cell projection, lamellipodium Cell projection, ruffle Note=Isoform 3 is mainly cytoplasmic and isoform 1 and isoform 3 are excluded from the nucleolus. Colocalizes with ITGB1 and ITGB1BP1 at the edge or peripheral ruffles and lamellipodia during the early stages of cell spreading on fibronectin or collagen but not on vitronectin or laminin substrates.
Domain PF00334 Nucleoside diphosphate kinase
Function

Major role in the synthesis of nucleoside triphosphates other than ATP. Negatively regulates Rho activity by interacting with AKAP13/LBC. Acts as a transcriptional activator of the MYC gene; binds DNA non-specifically (PubMed:8392752). Exhibits histidine protein kinase activity.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001678 cellular glucose homeostasis
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006165 nucleoside diphosphate phosphorylation
GO:0006171 cAMP biosynthetic process
GO:0006183 GTP biosynthetic process
GO:0006213 pyrimidine nucleoside metabolic process
GO:0006220 pyrimidine nucleotide metabolic process
GO:0006221 pyrimidine nucleotide biosynthetic process
GO:0006228 UTP biosynthetic process
GO:0006241 CTP biosynthetic process
GO:0006979 response to oxidative stress
GO:0007229 integrin-mediated signaling pathway
GO:0008544 epidermis development
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009132 nucleoside diphosphate metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009142 nucleoside triphosphate biosynthetic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009145 purine nucleoside triphosphate biosynthetic process
GO:0009147 pyrimidine nucleoside triphosphate metabolic process
GO:0009148 pyrimidine nucleoside triphosphate biosynthetic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009163 nucleoside biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009201 ribonucleoside triphosphate biosynthetic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0009206 purine ribonucleoside triphosphate biosynthetic process
GO:0009208 pyrimidine ribonucleoside triphosphate metabolic process
GO:0009209 pyrimidine ribonucleoside triphosphate biosynthetic process
GO:0009218 pyrimidine ribonucleotide metabolic process
GO:0009220 pyrimidine ribonucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009913 epidermal cell differentiation
GO:0010720 positive regulation of cell development
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0015949 nucleobase-containing small molecule interconversion
GO:0018106 peptidyl-histidine phosphorylation
GO:0018202 peptidyl-histidine modification
GO:0030099 myeloid cell differentiation
GO:0030216 keratinocyte differentiation
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030819 positive regulation of cAMP biosynthetic process
GO:0030856 regulation of epithelial cell differentiation
GO:0030858 positive regulation of epithelial cell differentiation
GO:0031346 positive regulation of cell projection organization
GO:0033500 carbohydrate homeostasis
GO:0034284 response to monosaccharide
GO:0034599 cellular response to oxidative stress
GO:0042278 purine nucleoside metabolic process
GO:0042451 purine nucleoside biosynthetic process
GO:0042455 ribonucleoside biosynthetic process
GO:0042593 glucose homeostasis
GO:0043434 response to peptide hormone
GO:0043588 skin development
GO:0045604 regulation of epidermal cell differentiation
GO:0045606 positive regulation of epidermal cell differentiation
GO:0045616 regulation of keratinocyte differentiation
GO:0045618 positive regulation of keratinocyte differentiation
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045666 positive regulation of neuron differentiation
GO:0045682 regulation of epidermis development
GO:0045684 positive regulation of epidermis development
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046036 CTP metabolic process
GO:0046039 GTP metabolic process
GO:0046051 UTP metabolic process
GO:0046058 cAMP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046129 purine ribonucleoside biosynthetic process
GO:0046131 pyrimidine ribonucleoside metabolic process
GO:0046132 pyrimidine ribonucleoside biosynthetic process
GO:0046134 pyrimidine nucleoside biosynthetic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046777 protein autophosphorylation
GO:0046939 nucleotide phosphorylation
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050769 positive regulation of neurogenesis
GO:0051259 protein oligomerization
GO:0051962 positive regulation of nervous system development
GO:0052652 cyclic purine nucleotide metabolic process
GO:0060416 response to growth hormone
GO:0070542 response to fatty acid
GO:0071229 cellular response to acid chemical
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0071396 cellular response to lipid
GO:0071398 cellular response to fatty acid
GO:0072522 purine-containing compound biosynthetic process
GO:0072527 pyrimidine-containing compound metabolic process
GO:0072528 pyrimidine-containing compound biosynthetic process
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901068 guanosine-containing compound metabolic process
GO:1901070 guanosine-containing compound biosynthetic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901652 response to peptide
GO:1901657 glycosyl compound metabolic process
GO:1901659 glycosyl compound biosynthetic process
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
Molecular Function GO:0004550 nucleoside diphosphate kinase activity
GO:0004673 protein histidine kinase activity
GO:0004674 protein serine/threonine kinase activity
GO:0005504 fatty acid binding
GO:0008144 drug binding
GO:0016775 phosphotransferase activity, nitrogenous group as acceptor
GO:0016776 phosphotransferase activity, phosphate group as acceptor
GO:0019205 nucleobase-containing compound kinase activity
GO:0019215 intermediate filament binding
GO:0031406 carboxylic acid binding
GO:0033293 monocarboxylic acid binding
GO:0043168 anion binding
Cellular Component GO:0001726 ruffle
GO:0005882 intermediate filament
GO:0030027 lamellipodium
GO:0031252 cell leading edge
GO:0043209 myelin sheath
GO:0045111 intermediate filament cytoskeleton
> KEGG and Reactome Pathway
 
KEGG hsa00230 Purine metabolism
hsa00240 Pyrimidine metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-6798695: Neutrophil degranulation
R-HSA-499943: Synthesis and interconversion of nucleotide di- and triphosphates
Summary
SymbolNME2
NameNME/NM23 nucleoside diphosphate kinase 2
Aliases NM23-H2; NDPKB; non-metastatic cells 2, protein (NM23B) expressed in; NDKB; NDPK-B; NM23B; PUF; HEL-S-155an; ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NME2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNME2
NameNME/NM23 nucleoside diphosphate kinase 2
Aliases NM23-H2; NDPKB; non-metastatic cells 2, protein (NM23B) expressed in; NDKB; NDPK-B; NM23B; PUF; HEL-S-155an; ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NME2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
Summary
SymbolNME2
NameNME/NM23 nucleoside diphosphate kinase 2
Aliases NM23-H2; NDPKB; non-metastatic cells 2, protein (NM23B) expressed in; NDKB; NDPK-B; NM23B; PUF; HEL-S-155an; ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NME2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0340.902
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0550.99
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0990.976
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1020.9
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2810.852
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5680.796
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4490.152
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.7830.197
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0720.915
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4360.881
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.870.849
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0610.57
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolNME2
NameNME/NM23 nucleoside diphosphate kinase 2
Aliases NM23-H2; NDPKB; non-metastatic cells 2, protein (NM23B) expressed in; NDKB; NDPK-B; NM23B; PUF; HEL-S-155an; ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NME2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNME2
NameNME/NM23 nucleoside diphosphate kinase 2
Aliases NM23-H2; NDPKB; non-metastatic cells 2, protein (NM23B) expressed in; NDKB; NDPK-B; NM23B; PUF; HEL-S-155an; ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NME2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NME2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNME2
NameNME/NM23 nucleoside diphosphate kinase 2
Aliases NM23-H2; NDPKB; non-metastatic cells 2, protein (NM23B) expressed in; NDKB; NDPK-B; NM23B; PUF; HEL-S-155an; ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NME2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNME2
NameNME/NM23 nucleoside diphosphate kinase 2
Aliases NM23-H2; NDPKB; non-metastatic cells 2, protein (NM23B) expressed in; NDKB; NDPK-B; NM23B; PUF; HEL-S-155an; ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NME2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNME2
NameNME/NM23 nucleoside diphosphate kinase 2
Aliases NM23-H2; NDPKB; non-metastatic cells 2, protein (NM23B) expressed in; NDKB; NDPK-B; NM23B; PUF; HEL-S-155an; ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NME2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNME2
NameNME/NM23 nucleoside diphosphate kinase 2
Aliases NM23-H2; NDPKB; non-metastatic cells 2, protein (NM23B) expressed in; NDKB; NDPK-B; NM23B; PUF; HEL-S-155an; ......
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NME2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting NME2.
ID Name Drug Type Targets #Targets
DB04315Guanosine-5'-DiphosphateSmall MoleculeADSSL1, ARF1, ARF4, ARF6, ARL1, ARL3, ARL5A, ARL5B, CDC42, EEF1A1, ......36